Advertisement

V. Craig Jordan, OBE, PhD, DSc, FMedSci, Receives Reynold Spector Award in Clinical Pharmacology


Advertisement
Get Permission

V. Craig Jordan, OBE, PhD, DSc, FMedSci

V. Craig Jordan, OBE, PhD, DSc, FMedSci

V. CRAIG JORDAN, OBE, PhD, DSc, FMedSci, of The University of Texas MD Anderson Cancer Center, will receive the 2019 Reynold Spector Award in Clinical Pharmacology, during the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology 2019 in Orlando, Florida, in April 2019. This award, which was established in 2014 in recognition of Dr. Spector’s contributions to clinical pharmacology, recognizes excellence in research and/or teaching in the field.

Dr. Jordan is being recognized for his basic, translational, and clinical pharmacology research, which resulted in the development of selective estrogen receptor modulators. These agents have expanded options for the management of estrogen receptor–positive breast cancers and osteoporosis in postmenopausal women.

Paula Stern, PhD

Paula Stern, PhD

Dr. Jordan was nominated by Paula Stern, PhD, of Northwestern University Feinberg School of Medicine. She noted: “Dr. Jordan’s translational research over the past 4 decades established the standard of care for the endocrine treatment of breast cancer, chemoprevention of breast cancer, and the first studies of the evolution of drug resistance to long-term antiestrogen therapy. Tamoxifen was the first [selective estrogen receptor modulators], but all [selective estrogen receptor modulators] have their origins in scientific discovery in Dr. Jordan’s laboratory.”


Advertisement

Advertisement



;
Advertisement